Related content

Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment

By Moon Joon   Kim Shi   Kang Byung   Chae Yee   Kim Jong   Baek Jin   Park Jae   Song Moo   Chung Joo   Won Jong   Lee Sang   Joo Young   Kim Yeo   Kim Hyeong   Jo Deog   Sohn Sang  

Annals of Hematology, Vol. 89, Iss. 7, 2010-07 ,pp. : 681-689

Springer Publishing Company

Access to resources Recommend Favorite

Absence of MLL gene rearrangement in de novo myelodysplastic syndromes (MDS)

By Pappa V.  

Annals of Hematology, Vol. 83, Iss. 3, 2004-03 ,pp. : 170-175

Springer Publishing Company

Access to resources Recommend Favorite

A limited number of 5-azacitidine cycles can be effective treatment in MDS

By Müller-Thomas Catharina   Schuster Tibor   Peschel Christian   Götze Katharina  

Annals of Hematology, Vol. 88, Iss. 3, 2009-03 ,pp. : 213-219

Springer Publishing Company

Access to resources Recommend Favorite

Wilms tumor gene peptide-based immunotherapy for patients with overt Leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis

By Oka Yoshihiro   Tsuboi Akihiro   Murakami Masaki   Hirai Manabu   Tominaga Nobuhiko   Nakajima Hiroko   Elisseeva Olga   Masuda Tomoki   Nakano Akiko   Kawakami Manabu   Oji Yusuke   Ikegame Kazuhiro   Hosen Naoki   Udaka Keiko   Yasukawa Masaki   Ogawa Hiroyasu   Kawase Ichiro   Sugiyama Haruo  

International Journal of Hematology, Vol. 78, Iss. 1, 2003-02 ,pp. : 56-61

Springer Publishing Company

Access to resources Recommend Favorite

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

By Giagounidis Aristoteles  

Annals of Hematology, Vol. 87, Iss. 5, 2008-05 ,pp. : 345-352

Springer Publishing Company

Access to resources Recommend Favorite